Skip to main content
Fig. 3 | Journal of Biomedical Science

Fig. 3

From: Oleuropein suppresses endometriosis progression and improves the fertility of mice with endometriosis

Fig. 3

Suppression of the growth of mouse and human ectopic lesions in mice with endometriosis by oleuropein. a Oleuropein treatment plan. After ectopic lesions were established in different mouse models (21 days), the mice were randomly separated and then orally treated with vehicle or oleuropein (25 mg/kg or 200 mg/kg, once a day, 31 days). b Inhibition of mouse ectopic lesion progression in mice with endometriosis using heterotransplantation with luciferase-labeled endometrial tissues. Oleuropein treatment (25 mg/kg) significantly reduced the luciferase activity of ectopic lesions in mice with endometriosis. However, 200 mg/kg oleuropein did not suppress luciferase activity compared to the vehicle. c Reduction in the volume of ectopic lesions by oleuropein. Endometriosis was induced in mice with the autotransplantation method. Ectopic lesions were isolated from mice with endometriosis after 31 days of oleuropein or vehicle treatment. The volume of ectopic lesions was determined using the modified ellipsoid Formula 1/2(Length × Width2) [23]. d Inhibition of the progression of human ectopic lesions by oleuropein. Human ectopic lesions were generated in SCID female mice by heterotransplantation with the cultured human endometrial cell method. After establishing the human ectopic lesion (21 days after endometriosis induction), SCID mice with endometriosis were treated with oleuropein (25 mg/kg, once a day, 21 days) or vehicle. Oleuropein treatment significantly reduced the luciferase activity of human ectopic lesions. OLE, oleuropein. *, P < 0.05

Back to article page